Topic 14 — Tetracyclines and Aminoglycosides

Connect the major pharmacological concepts into one rapid-revision flow: ribosomal target → antibacterial effect → pharmacokinetic behavior → clinical use → toxicity and resistance.

1. THE TOPIC IN ONE CONNECTED FLOW

Tetracyclines and aminoglycosides both inhibit bacterial protein synthesis at the 30S ribosomal subunit, but they behave differently. Tetracyclines mainly stop bacterial growth, whereas aminoglycosides cause bactericidal injury. Their absorption, distribution and elimination then determine where they are useful and which toxicities must be anticipated.

Protein synthesis required

Bacterial growth depends on functional 30S and 50S ribosomes

→

30S drug target

Tetracyclines and aminoglycosides reach the bacterial 30S subunit

→

Two different mechanisms

Tetracyclines → block aminoacyl-tRNA attachment
Aminoglycosides → disturb initiation and cause mRNA misreading

→

Different antibacterial effects

Tetracyclines → mainly bacteriostatic
Aminoglycosides → bactericidal

→

PK determines use

Tetracyclines: oral absorption affected by minerals
Aminoglycosides: poor oral absorption → systemic use is parenteral

→

Clinical application

Tetracyclines → atypical/intracellular organisms
Aminoglycosides → serious aerobic Gram-negative infections

→

Major cautions

Tetracyclines → teeth/bone effects, pregnancy caution
Aminoglycosides → nephrotoxicity and ototoxicity

2. KEY CLINICAL CONNECTIONS

Tetracycline Absorption → Clinical Failure

Calcium, iron, magnesium or aluminium
→
chelate formation in the gut
→
reduced oral absorption
→
lower effective drug exposure.

This explains why dairy products, iron preparations and antacids can reduce tetracycline effectiveness.

Aminoglycoside PK–PD → Bacterial Killing

High effective peak concentration
→
greater concentration-dependent killing
→
persistent suppression after levels fall
→
post-antibiotic effect.

These two properties explain why aminoglycoside activity is linked strongly to peak concentration rather than continuous exposure alone.

Drug Distribution → Characteristic Toxicity

Tetracycline calcium binding
→
deposition in developing teeth and bone
→
discoloration and fetal skeletal/dental effects.

Aminoglycoside renal/inner-ear accumulation
→
tubular and sensory-cell injury
→
nephrotoxicity and ototoxicity.

3. AIM HIGH-YIELD INTEGRATION REVIEW

⭐ 30S target → different outcomes: tetracyclines reversibly inhibit aminoacyl-tRNA attachment and mainly stop growth, whereas aminoglycosides cause faulty translation and bacterial death.

⭐ Minerals → poor tetracycline absorption: calcium, iron, magnesium and aluminium form poorly absorbed complexes, reducing effective oral therapy.

Intracellular penetration → clinical use: tetracyclines are useful against important atypical organisms including rickettsiae, chlamydiae and mycoplasma.

Calcium binding → developmental toxicity: deposition in developing teeth and bone explains tooth discoloration and avoidance during pregnancy.

Outdated tetracycline → tubular injury: toxic degradation products can damage proximal tubules and produce a Fanconi-like syndrome.

⭐ Oxygen-dependent uptake → antibacterial spectrum: aminoglycosides work best against aerobic Gram-negative bacilli and have poor activity against anaerobes.

⭐ Renal elimination → toxicity risk: declining renal function reduces aminoglycoside clearance, causing accumulation and increasing nephrotoxic and ototoxic risk.

Resistance follows drug behavior: tetracycline resistance commonly involves efflux or ribosomal protection, whereas aminoglycosides are commonly inactivated by drug-modifying enzymes.

AIM Exam Trap: Both drug classes act on the 30S subunit, but tetracyclines are mainly bacteriostatic, whereas aminoglycosides are bactericidal.